Earnings release · BMY
Bristol Myers Squibb Co. · Filed · SEC Form 8-K, Item 2.02
Revenue climbed 7% year on year to $13.1 billion, and EPS was $1.05. The company lifted its guidance, which is usually read as management's view of coming periods improving.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
$13.1 billion +7% vs a year ago
…Third quarter revenues increased 7% to $13.1 billion…
$1.05
…GAAP EPS was $1.05 and non-GAAP EPS was $1.35; Both figures include net impact of $(0.58) due to Acquired IPRD charges and licensing income…
Guidance raised
…Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 and Raises Full-Year Revenue Outlook.…
BMY trades at 9.3x P/E and a 4.5% yield while three forensic mispricings sit in plain sight: the Eliquis IRA cliff that didn't happen, a growth/legacy crossover already cleared in 2025, and a $14B Cobenfy option the Street is valuing at zero. Rating: BUY. 12-month target $78, multi-year intrinsic $95+.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
